Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus pemetrexed-platinum chemotherapy in advanced non-squamous non-small cell lung cancer
ChiCTR1800015920Phase 4Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Apr 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR1800015920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015920.